Black Diamond Therapeutics Inc

BDTX

Company Profile

  • Business description

    Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

  • Contact

    245 First Street
    18th Floor
    CambridgeMA02142
    USA

    T: +1 617 252-0848

    https://www.blackdiamondtherapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    21

Stocks News & Analysis

stocks

7 undervalued US stocks that crushed earnings

Arista and GE Vernova remain among the cheapest Morningstar-covered stocks after strong earnings beats.
stocks

Undervalued ASX share hitting on all cylinders

Strong performance across all segments in latest earnings release.
stocks

Investor Playbook: Can your portfolio handle what’s next?

Testing portfolio resilience in an uncertain market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,165.4039.10-0.42%
CAC 408,389.2220.310.24%
DAX 4026,745.854.10-0.02%
Dow JONES (US)52,347.5550.460.10%
FTSE 10010,942.1539.590.36%
HKSE23,753.84116.240.49%
NASDAQ25,136.27229.82-0.91%
Nikkei 22559,662.021,480.33-2.42%
NZX 50 Index14,303.77130.090.92%
S&P 5007,561.6730.73-0.40%
S&P/ASX 2009,044.7037.50-0.41%
SSE Composite Index3,602.5731.78-0.87%

Market Movers